Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00505752 · ClinicalTrials.gov registry record · Phase 2
Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)
A Phase 2 study of Infertility, sponsored by Merck KGaA, Darmstadt, Germany.
- Completed
- Registry status
- Phase 2
- Development phase
- 520
- Enrollment target
- 1
- Study location
NCT00505752 is a Phase 2 study of Infertility that has completed, run by Merck KGaA, Darmstadt, Germany. The registered enrollment target is 520 participants, below the 7,582-participant average among 74 other Infertility trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00505752, a Phase 2 study of Infertility, has completed, sponsored by Merck KGaA, Darmstadt, Germany.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 520 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive technology (ART) procedure (In vitro fertilization/Intra cytoplasmic sperm injection \[IVF/ICSI\]). This study will compare 3 doses of the investigational drug versus a currently marketed drug follitropin alfa (Gonal-f® revised formulation female \[RFF\] Pen) in regards to the number of fertilized oocytes.
Conditions Studied
Interventions
- DRUG AS900672-Enriched 50 microgram (mcg)
- DRUG AS900672-Enriched 100 mcg
- DRUG AS900672-Enriched 150 mcg
- DRUG Follitropin alfa 150 international unit (IU)
- DRUG Recombinant human chorionic gonadotropin (r-hCG)
Study Locations (1)
Massachusetts
- Local US Medical Information Office - Rockland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2007-01 |
| Est. Completion | 2008-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00505752
The ClinicalTrials.gov registry entry for NCT00505752 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 520 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 7,582-participant average among 74 other Infertility trials with a reported enrollment target (93% lower). The listed sponsor is Merck KGaA, Darmstadt, Germany, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Infertility appearing as the primary indexed condition, and to 5 interventions - of which AS900672-Enriched 50 microgram (mcg) is the first listed.
NCT00505752 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00505752 about?
NCT00505752 is a clinical study titled "Investigation of a Long-Acting Follicle Stimulating Hormone in Infertile Women Undergoing Assisted Reproductive Technology (ART)". This is a Phase 2, interventional, prospective, multi-center, randomized, assessor-blind, active-comparator, dose-finding study to evaluate a new investigational long-acting follicle stimulating hormone (FSH) in infertile women who are undergoing an assisted reproductive technology (ART) procedure (...
What is the current status of trial NCT00505752?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 520 participants. The study started on 2007-01. Estimated completion is 2008-09.
What conditions does trial NCT00505752 study?
This clinical trial studies the following conditions: Infertility.
What interventions are being tested in trial NCT00505752?
The interventions under investigation include: AS900672-Enriched 50 microgram (mcg) (DRUG), AS900672-Enriched 100 mcg (DRUG), AS900672-Enriched 150 mcg (DRUG), Follitropin alfa 150 international unit (IU) (DRUG), Recombinant human chorionic gonadotropin (r-hCG) (DRUG).
Who is sponsoring clinical trial NCT00505752?
This trial is sponsored by Merck KGaA, Darmstadt, Germany, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00505752 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Infertility
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Benefits of Walnuts for Male Reproductive Health
COMPLETED · Phase 2
-
Gamete Treatment to Correct Fertilization Failure
RECRUITING · NA
-
Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome
RECRUITING · Phase 1
-
Non-Euploid Embryo Transfer (NEET) Registry
RECRUITING
-
Validating Incubators in the Lab: Optimizing Culture and Investigating blasTulation Yield
RECRUITING · NA
-
Apple Women's Health Study
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.